{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(1)"],"submitter":["Chen L"],"pubmed_abstract":["The evaluation of predictive biomarkers in advanced lung cancer requires methods that can comprehensively profile rare cell populations. We developed a dual-labeling assay integrating tyramide signal amplification immunofluorescence (TSA-IF) with fluorescence <i>in situ</i> hybridization (FISH) to concurrently detect protein expression and chromosomal aberrations. This approach was used to analyze PD-L1-positive circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and white blood cells (WBCs) from multiple biofluid types. Our assay improved signal integrity and revealed distinct clinical associations: specific PD-L1<sup>+</sup> CTC phenotypes were linked to metastasis and correlated with improved immunotherapy response, whereas PD-L1<sup>+</sup> CTECs were associated with treatment resistance and serum tumor markers. Furthermore, PD-L1<sup>+</sup> WBC levels were strongly correlated with C-reactive protein, connecting them to systemic inflammation. This integrated liquid biopsy strategy enables a multifaceted view of the tumor microenvironment and host immune status, presenting a conceptual advance for monitoring treatment efficacy and inflammatory activity in advanced lung cancer."],"journal":["iScience"],"pagination":["114357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12799786"],"repository":["biostudies-literature"],"pubmed_title":["Analyzed PD-L1-positive subpopulations by dual-labeling TSA-IF-FISH predicts immunotherapy efficacy in advanced lung cancer."],"pmcid":["PMC12799786"],"pubmed_authors":["Yang Z","Li S","Lu Y","Chen L","Tang D","Zhang L"],"additional_accession":[]},"is_claimable":false,"name":"Analyzed PD-L1-positive subpopulations by dual-labeling TSA-IF-FISH predicts immunotherapy efficacy in advanced lung cancer.","description":"The evaluation of predictive biomarkers in advanced lung cancer requires methods that can comprehensively profile rare cell populations. We developed a dual-labeling assay integrating tyramide signal amplification immunofluorescence (TSA-IF) with fluorescence <i>in situ</i> hybridization (FISH) to concurrently detect protein expression and chromosomal aberrations. This approach was used to analyze PD-L1-positive circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and white blood cells (WBCs) from multiple biofluid types. Our assay improved signal integrity and revealed distinct clinical associations: specific PD-L1<sup>+</sup> CTC phenotypes were linked to metastasis and correlated with improved immunotherapy response, whereas PD-L1<sup>+</sup> CTECs were associated with treatment resistance and serum tumor markers. Furthermore, PD-L1<sup>+</sup> WBC levels were strongly correlated with C-reactive protein, connecting them to systemic inflammation. This integrated liquid biopsy strategy enables a multifaceted view of the tumor microenvironment and host immune status, presenting a conceptual advance for monitoring treatment efficacy and inflammatory activity in advanced lung cancer.","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T13:18:31.638Z","creation":"2026-05-31T03:07:26.622Z"},"accession":"S-EPMC12799786","cross_references":{"pubmed":["41541685"],"doi":["10.1016/j.isci.2025.114357"]}}